SCHEMBL520376

SCHEMBL520376

COc1ccc(-c2cc(Cl)c3cnc(SC)nn23)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
FYN P06241 4/20 0.40
JAK2 O60674 1/20 0.38
KDR P35968 1/20 0.37
CYP2A6 P11509 1/20 0.37
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
DYRK3 O43781 1/20 0.37
DYRK1A Q13627 1/20 0.37
DYRK2 Q92630 1/20 0.37
ACLY P53396 1/20 0.36
F2RL3 Q96RI0 3/20 0.36
PIK3CA P42336 1/20 0.35
HSD17B1 P14061 1/20 0.35
HSD17B2 P37059 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA1 Q13131 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL522580 0.83 FYN (0.44) FYNJAK2KDRCYP2A6PDGFRB
SCHEMBL521391 0.79 ACLY (0.41) FYNJAK2KDRPDGFRBPDGFRA
SCHEMBL4494425 0.67 ADORA2A (0.50) ADORA2AADORA1CYP2A6PDGFRBPDGFRA
SCHEMBL521048 0.65 JAK2 (0.52) JAK2CYP3A4
SCHEMBL520225 0.64 KDM4E (0.49) KDRKDM4ECTDSP1
SCHEMBL13234221 0.64 FYN (0.68) FYNKDRDYRK3DYRK1ADYRK2
SCHEMBL31174412 0.64 CYP2A6 (0.68) FYNCYP2A6PDGFRBPDGFRAPIK3CA
SCHEMBL3754419 0.64 CYP2A6 (0.68) FYNCYP2A6PDGFRBPDGFRAPIK3CA
SCHEMBL520341 0.63 KCNH2 (0.41) CYP2C9
SCHEMBL14934093 0.62 PIK3CA (0.52) FYNCYP2A6PDGFRBPDGFRAPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 ADORA2A 4337/4885ADORA1 4120/4885FYN 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.